ClinicalTrials.gg
TerminatedNCT00434226Updated Nov 17, 2026Results posted

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

A Phase 2 interventional study of bevacizumab and sunitinib in Non-Small Cell Lung Cancer, sponsored by Genentech, Inc.. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Based on data collected, the combination appeared to be poorly tolearated.
Updated Nov 17, 2026Posted results revisedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Sunitinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 19
56 · median 80
Started
2007
with 5 others
Phase 2
12 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
1 of 19
Genentech, Inc.

Among the 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 6 that started in 2007, is one of 12 in phase 2, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About sunitinib

Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing sunitinib in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced, recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC. All patients will have advanced, histologically or cytologically confirmed NSCLC (Stage IIIb with pleural effusions, Stage IV, or recurrent).

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • SABER-L
  • NSCLC
  • Avastin
  • Sutent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form
  • Age ≥ 18 years
  • Advanced or cytologically confirmed NSCLC (Stage IIIb with malignant pleural or pericardial effusion, Stage IV, or recurrent)
  • Measurable or non-
  • Patients with treated are eligible if there is no evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period (brain imaging to be competed Day -7 to Day 1).
  • Prior treatment for CNS disease as deemed appropriate by the treating physician
  • performance status 0 or 1
  • Ability and willingness to comply with study and follow-up procedures

Exclusion criteria

Exclusion Criteria:

  • Prior systemic chemotherapy for disease
  • Active other than lung cancer
  • Current, recent, or planned participation in another experimental drug study
  • Prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib
  • chemotherapy or prior combined modality neoadjuvant therapy (chemotherapy plus radiotherapy with or without surgery) within 6 months prior to Day 1 of Cycle 1
  • of \< 12 weeks
  • Current, recent, or planned participation in an experimental drug study
  • Inability to take oral medication or requirement of IV alimentation or total parenteral nutrition, or prior surgical procedures affecting absorption
  • Inadequate organ function
  • Known evidence of disseminated intravascular coagulopathy
  • Active infection or fever > 38.5°C within 3 days prior to Day 1 of Cycle 1
  • Untreated abnormal thyroid function tests as defined by institutional standards (patients with controlled hypothyroidism are eligible for study participation)
  • Any other medical condition(s) (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide , cooperate, or participate in the study, or to interfere with the interpretation of the results
  • Intrathoracic lung carcinoma of squamous cell histology
  • Known CNS disease except for treated
  • Inadequately controlled hypertension
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • (NYHA) Class II or greater CHF
  • History of myocardial infarction or unstable angina within 12 months prior to Day 1 of Cycle 1
  • History of stroke or within 12 months prior to Day 1 of Cycle 1
  • Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1 of Cycle 1
  • History of hemoptysis within 1 month prior to Day 1 of Cycle 1
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for major surgical procedure during the course of the study
  • Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of Cycle 1
  • History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of Cycle 1
  • Serious, non-healing wound, active ulcer, or untreated bone fracture
  • Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
  • Known to any component of bevacizumab or sunitinib
  • Pregnancy (positive pregnancy test) or lactation
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Bevacizumab + Carboplatin/Paclitaxel + Sunitinib

    Drug: bevacizumab · Drug: sunitinib · Drug: carboplatin · Drug: paclitaxel

  • Placebo comparator
    Bevacizumab + Carboplatin/Paclitaxel

    Drug: bevacizumab · Drug: carboplatin · Drug: paclitaxel

Interventions

  • Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle

  • 25 mg/day for 2 weeks, followed by 1 week of rest

  • On the first day of each cycle for 4 cycles

  • On the first day of each cycle for 4 cycles

06

What researchers measure

Primary outcomes

  1. Best Response

    The best overall response is the best response, per RECIST criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.

    Time frame: From randomization until disease progression/recurrence

Secondary outcomes

  1. Serious Adverse Events

    All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

    Time frame: 60 days following the last administration of study treatment

  2. Incidence of Grade ≥ 3 Adverse Events

    All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

    Time frame: 60 days following the last administration of study treatment

  3. Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction

    All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

    Time frame: 60 days following the last administration of study treatment

  4. Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption

    All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

    Time frame: 60 days following the last administration of study treatment

07

Results

Posted Aug 21, 2009
Limitations and caveats
Based on the early safety results from this study, Genentech halted further recruitment and discontinued treatment. Insufficient efficacy data was available to perform additional analyses and limited the interpretation of the analyses performed.

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/Paclitaxel
Started3026
Completed00
Not completed3026

Outcome measures

PrimaryBest Response

The best overall response is the best response, per RECIST criteria, recorded from randomization until disease progression/recurrence (includes both confirmed and unconfirmed responses). Although the original primary outcome was progression-free survival, there was insufficient data available to report on that outcome.

Time frame:
From randomization until disease progression/recurrence
Reported as:
Number · participants
Best Response
participantsBevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/Paclitaxel
Complete Response00
Partial Response129
Stable Disease109
Progressive Disease21
Unable to Evaluate00
Missing10
SecondarySerious Adverse Events

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Time frame:
60 days following the last administration of study treatment
Reported as:
Number · participants
Serious Adverse Events
participantsBevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/Paclitaxel
Anaemia01
Febrile Neutropenia41
Neutropenia10
Thrombocytopenia10
Cardiac Arrest11
Diarrhoea10
Asthenia01
Disease Progression11
Fatigue10
Pain01
Hepatic Pain01
Drug Hypersensitivity01
Cellulitis10
Bacterial Sepsis01
Collapse of Lung10
Platelet Count Decreased10
Haemoglobin Decreased01
Nutrophil Count Decreased01
Dehydration21
Back Pain10
Lung Cancer Metastatic02
Gastric Cancer10
Non-Small Cell Lung Cancer10
Confusional State01
Renal Failure01
Pleural Effusion02
Pneumothorax10
Chronic Obstructive Pulmonary Disease02
Pulmonary Embolism20
Dyspnoea01
Haemoptysis01
Pneumonitis10
Pulmonary Haemorrhage01
Nasal Septum Perforation10
Aortic Aneurysm10
Hypotension01
SecondaryIncidence of Grade ≥ 3 Adverse Events

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Time frame:
60 days following the last administration of study treatment
Reported as:
Number · participants
Incidence of Grade ≥ 3 Adverse Events
participantsBevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/Paclitaxel
Anaemia10
Febrile Nutropenia42
Leukopenia63
Neutropenia1812
Thrombocytopenia75
Cardiac Arrest11
Left Ventricular Dysfunction10
Diarrhoea11
Gastrointestinal Haemorrhage10
Asthenia01
Disease Progression11
Fatigue23
Pain12
Hepatic Pain01
Drug Hypersensitivity01
Hypersensitivity01
Bacterial Sepsis01
Cellulitis10
Infection10
Pneumonia02
Collapse of Lung10
Aspartate Aminotransferase Increased10
Blood Alkaline Phosphatase Increased10
Fibrin D Dimer Increased10
Haemoglobin Decreased01
International Normalised Ratio Increased11
Nutrophil Count Decreased11
Platelet Count Decreased40
White Blood Cell Count Decreased20
Anorexia10
Dehydration21
Hyperglycaemia02
Hypoalbuminaemia10
Hypocalcaemia01
Hyponatraemia02
Arthralgia01
Back Pain10
Muscular Weakness10
Musculoskeletal Pain10
Gastric Cancer10
Lung Cancer Metastatic02
Metastases to Central Nervous System10
Non-Small Cell Lung Cancer10
Dizziness10
Confusional State01
Albuminuria10
Renal Failure01
Chronic Obstructive Pulmonary Disease01
Dyspnoea22
Pleural Effusion02
Pneumonitis10
Pulmonary Embolism21
Pulmonary Haemorrhage01
Leukocytoclastic Vasculitis10
Rash20
Aortic Aneurysm10
Hypertension31
SecondaryIncidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Time frame:
60 days following the last administration of study treatment
Reported as:
Number · participants
Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction
participantsBevacizumab + Carboplatin/Paclitaxel + Sunitinib
Anaemia1
Febrile Nutropenia2
Leukopenia4
Neutropenia11
Thrombocytopenia6
Left Ventricular Dysfunction1
Diarrhoea1
Gastrointestinal Haemorrhage1
Nausea1
Stomatitis1
Disease Progression1
Fatigue2
Bronchitis1
Cellulitis1
Infection1
Collapse of Lung1
Aspartate Aminotransferase Increased1
Fibrin D Dimer Increased1
International Normalised Ratio Increased1
Neutrophil Count Decreased1
Platelet Count Decreased5
White Blood Cell Count Decreased1
Anorexia1
Dehydration2
Hypoalbuminaemia1
Back Pain1
Muscular Weakness1
Musculoskeletal Pain1
Gastric Cancer1
Metastases to Central Nervous System1
Non-Small Cell Lung Cancer1
Dizziness1
Albuminuria1
Pnemothorax1
Dyspnoea2
Pulmonary Embolism2
Leukocytoclastic Vasculitis1
Rash1
Aortic Aneurysm1
Hypertension3
SecondaryIncidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption

All grades according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0

Time frame:
60 days following the last administration of study treatment
Reported as:
Number · participants
Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption
participantsBevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/Paclitaxel
Anaemia10
Febrile Nutropenia11
Leukopenia11
Neutropenia31
Thrombocytopenia32
Cardiac Arrest01
Diarrhoea10
Gastrointestinal Haemorrhage10
Disease Progression12
Fatigue21
Drug Hypersensitivity01
Hypersensitivity01
Bronchitis10
Infection10
Collapse of Lung10
Aspartate Aminotransferase Increased10
International Normalised Ratio Increased10
Neutrophil Count Decreased01
Platelet Count Decreased50
Dehydration20
Back Pain10
Gastric Cancer10
Lung Cancer Metastatic01
Metastases to Central Nervous System10
Metastases to Liver01
Non-Small Cell Lung Cancer10
Albuminuria10
Renal Failure01
Haemoptysis01
Pleural Effusion01
Pneumothorax10
Pulmonary Embolism20
Rash10
Aortic Aneurysm10
Hypertension22
Hypotension01

Adverse events

Collected over 60 days following the last administration of study treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Carboplatin/Paclitaxel7/26 (26.9%)15/26 (57.7%)25/26 (96.2%)
Bevacizumab + Carboplatin/Paclitaxel + Sunitinib11/29 (37.9%)17/29 (58.6%)28/29 (96.6%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventBevacizumab + Carboplatin/PaclitaxelBevacizumab + Carboplatin/Paclitaxel + Sunitinib
Febrile NeutropeniaBlood and lymphatic system disorders1/264/29
Lung Cancer MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/260/29
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/260/29
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders2/260/29
DehydrationMetabolism and nutrition disorders1/262/29
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/262/29
Cardiac ArrestCardiac disorders1/261/29
AstheniaGeneral disorders1/260/29
Disease ProgressionGeneral disorders1/261/29
Hepatic PainHepatobiliary disorders1/260/29
Most frequent other events
Showing 10 of 19
Most frequent other events
EventBevacizumab + Carboplatin/PaclitaxelBevacizumab + Carboplatin/Paclitaxel + Sunitinib
NeutropeniaBlood and lymphatic system disorders12/2618/29
ThrombocytopeniaBlood and lymphatic system disorders5/267/29
LeukopeniaBlood and lymphatic system disorders3/266/29
Platelet count decreasedInvestigations0/265/29
Febrile neutropeniaBlood and lymphatic system disorders2/264/29
FatigueGeneral disorders3/262/29
Pleural effusionRespiratory, thoracic and mediastinal disorders3/260/29
HypertensionVascular disorders3/263/29
PainGeneral disorders2/261/29
PneumoniaInfections and infestations2/260/29

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/PaclitaxelTotal
Mean63.7 ± 9.564.8 ± 10.764.2 ± 10.0
Age, Customized
Age, Customized(Participants)Bevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/PaclitaxelTotal
<18 Years000
Between 18 and 64 Years151328
>=65 Years151328
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Carboplatin/Paclitaxel + SunitinibBevacizumab + Carboplatin/PaclitaxelTotal
Female141226
Male161430
08

Study locations

No study locations are listed for this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2007 to primary completion in Apr 2008, 13 months.

Results were first posted in Aug 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2007
First posted
Feb 13, 2007
StartActual
Mar 27, 2007
Primary completionActual
Apr 29, 2008
CompletionActual
Apr 29, 2008
Results first posted
Aug 21, 2009
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 17, 2026
Study completion
Set to Apr 29, 2008 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Posted results revised
    Study completion Set to Apr 29, 2008 (now actual)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00434226
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 13, 2007
Start date
Mar 27, 2007
Primary completion
Apr 29, 2008
Completion
Apr 29, 2008
Results posted
Aug 21, 2009
Last update
Nov 17, 2026

Study contacts

Julie Hambleton, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunitinib

Start the discussion